BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34643020)

  • 1. Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.
    Pedersen-Bjergaard U; Agesen RM; Brøsen JMB; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen TJ; Juhl CB; Jensen AK; Lerche SS; Nørgaard K; Parving HH; Sørensen AL; Tarnow L; Thorsteinsson B
    Diabetes Obes Metab; 2022 Feb; 24(2):257-267. PubMed ID: 34643020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.
    Agesen RM; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    BMC Endocr Disord; 2019 Jul; 19(1):78. PubMed ID: 31337371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia.
    Brøsen JMB; Agesen RM; Alibegovic AC; Ullits Andersen H; Beck-Nielsen H; Gustenhoff P; Krarup Hansen T; Hedetoft CGR; Jensen TJ; Stolberg CR; Bogh Juhl C; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    Diabetes Technol Ther; 2022 Sep; 24(9):643-654. PubMed ID: 35467938
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
    Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
    JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
    Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
    JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of insulin degludec versus insulin glargine U100 on nocturnal glycaemia assessed by plasma glucose profiles in people with type 1 diabetes prone to nocturnal severe hypoglycaemia.
    Brøsen JMB; Agesen RM; Kristensen PL; Alibegovic AC; Andersen HU; Beck-Nielsen H; Gustenhoff P; Hansen TK; Hedetoft C; Jensen T; Stolberg CR; Juhl CB; Lerche SS; Nørgaard K; Parving HH; Tarnow L; Thorsteinsson B; Pedersen-Bjergaard U
    Diabetes Obes Metab; 2023 Jun; 25(6):1557-1565. PubMed ID: 36749303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
    Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
    Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
    DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
    Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Heller S; Buse J; Fisher M; Garg S; Marre M; Merker L; Renard E; Russell-Jones D; Philotheou A; Francisco AM; Pei H; Bode B;
    Lancet; 2012 Apr; 379(9825):1489-97. PubMed ID: 22521071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
    Philis-Tsimikas A; Lane W; Pedersen-Bjergaard U; Wysham C; Bardtrum L; Harring S; Heller S
    Diabetes Obes Metab; 2020 May; 22(5):779-787. PubMed ID: 31903697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Degludec hospital trial: A randomized controlled trial comparing insulin degludec U100 and glargine U100 for the inpatient management of patients with type 2 diabetes.
    Galindo RJ; Pasquel FJ; Vellanki P; Alicic R; Lam DW; Fayfman M; Migdal AL; Davis GM; Cardona S; Urrutia MA; Perez-Guzman C; Zamudio-Coronado KW; Peng L; Tuttle KR; Umpierrez GE
    Diabetes Obes Metab; 2022 Jan; 24(1):42-49. PubMed ID: 34490700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
    Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
    Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of major cardiovascular events, severe hypoglycaemia, and all-cause mortality for users of insulin degludec versus insulin glargine U100-A Danish cohort study.
    Jensen MH; Hejlesen O; Vestergaard P
    Diabetes Metab Res Rev; 2020 Jan; 36(1):e3225. PubMed ID: 31647163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
    Bode BW; Buse JB; Fisher M; Garg SK; Marre M; Merker L; Renard E; Russell-Jones DL; Hansen CT; Rana A; Heller SR;
    Diabet Med; 2013 Nov; 30(11):1293-7. PubMed ID: 23710902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with type 1 diabetes prone to severe hypoglycaemia: The HypoAna trial.
    Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Christiansen JS; Jensen T; Hougaard P; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
    Diabetes Metab; 2016 Sep; 42(4):249-55. PubMed ID: 27068361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.